Sultiame
产品说明书
 |
同义名 : | Sulthiame |
| CAS号 : | 61-56-3 | |
| 货号 : | A637802 | |
| 分子式 : | C10H14N2O4S2 | |
| 纯度 : | 99%+ | |
| 分子量 : | 290.36 | |
| MDL号 : | MFCD00865304 | |
| 存储条件： |
Pure form Sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Sultiame is a carbonic anhydrase (CA) inhibitor, widely used as an antiepileptic drug[2]. CA inhibitors (CAIs) such as acetazolamide, methazolamide, topiramate, zonisamide, and sulthiame (Sultiame) can reduce seizures through perturbation of the CO(2) equilibrium and/or the inhibition of ion channels[3]. Drugs inhibiting metabolism include antibiotic macrolides, chloramphenicol, isoniazide, some sulphonamides, propoxyphene, cimetidine, valproic acid and sulthiame. Anti-epileptic drugs can induce hepatic microsomal enzymes and, therefore, may increase metabolism of corticosteroids, oral contraceptives, oral anticoagulants, cardiovascular agents, antibiotics, chemotherapeutic agents, psychotropic drugs and non-opiate analgesics, thereby reducing their efficacy[4]. The high tolerability, efficacy, convenience of use and low cost suggest that sulthiame should become a first line drug in the benign partial epilepsies of childhood and juvenile myoclonic epilepsy. It also has a role as add-on treatment in other partial and myoclonic epilepsies[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03400189 | Epilepsy | Phase 1 | Active, not recruiting | August 30, 2018 | Switzerland ... 展开 >> Division of Clinical Pharmacology Lausanne, Vaud, Switzerland, 1011 收起 << |
| NCT00471744 | Epilepsy, Rolandic | Phase 3 | Terminated(low patient number ... 展开 >>after 2 years recruiting) 收起 << | - | Germany ... 展开 >> Dr. von Haunersches Kinderspital München, Germany, 81371 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.44mL 0.69mL 0.34mL |
17.22mL 3.44mL 1.72mL |
34.44mL 6.89mL 3.44mL |
| 参考文献 |
|---|